Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 20/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 20/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 20/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 20/20 | 1.00 |
| ▸ | GRIK1 | P39086 | 13/20 | 1.00 |
| ▸ | GRIK2 | Q13002 | 13/20 | 1.00 |
| ▸ | GRIK3 | Q13003 | 13/20 | 1.00 |
| ▸ | GRIK4 | Q16099 | 13/20 | 1.00 |
| ▸ | GRIK5 | Q16478 | 13/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7479472 | 0.93 | GRIA1 (0.87) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8674238 | 0.91 | GRIA1 (0.84) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8674522 | 0.90 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8672085 | 0.90 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7972520 | 0.90 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7976407 | 0.85 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8675872 | 0.85 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8673956 | 0.83 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8676905 | 0.83 | GRIA1 (0.71) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8686136 | 0.83 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-5849743-A | Quinoxalines and drugs prepared therefrom | BASF AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | GRM5, GRM1, GRM3 | GRIA1 10/4885GRIA2 13/4885GRIA3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.